InsiderTrades.com logo
True paradigm shift
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Daniel E. Geffken net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Daniel Geffken Biography and Net Worth

CFO of Eloxx Pharmaceuticals
Mr. Daniel Geffken was appointed as Interim Chief Financial Officer on April 1, 2021. Mr. Geffken is a founder of Danforth Advisors and brings more than 30 years of financial experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with over a billion dollars in market capitalization. He has served as chief financial officer and strategic consultant to numerous companies, including Apellis Pharmaceuticals, Cidara Therapeutics, GenePeeks, Homology Medicines, Stealth BioTherapeutics and Transkaryotic Therapies. Since 2013, Mr. Geffken has participated in eleven initial public offerings. Over the course of his career, he has helped life sciences companies raise more than two billion dollars in equity and debt securities. Mr. Geffken holds a B.S. from The Wharton School, University of Pennsylvania, and an M.B.A. from Harvard Business School.

How old is Daniel E. Geffken?

Mr. Geffken is currently 67 years old. There are 1 older executives and no younger executives at Eloxx Pharmaceuticals. Learn More on Daniel E. Geffken's age.

How do I contact Daniel E. Geffken?

The corporate mailing address for Mr. Geffken and other Eloxx Pharmaceuticals executives is 950 WINTER STREET, WALTHAM MA, 02451. Eloxx Pharmaceuticals can also be reached via phone at (781) 577-5300 and via email at [email protected]. Learn More on Daniel E. Geffken's contact information.

Has Daniel E. Geffken been buying or selling shares of Eloxx Pharmaceuticals?

Daniel E. Geffken has not been actively trading shares of Eloxx Pharmaceuticals during the last ninety days. Most recently, on Monday, November 29th, Daniel E. Geffken bought 50,000 shares of Eloxx Pharmaceuticals stock. The stock was acquired at an average cost of $0.72 per share, with a total value of $36,000.00. Learn More on Daniel E. Geffken's trading history.

Who are Eloxx Pharmaceuticals' active insiders?

Eloxx Pharmaceuticals' insider roster includes Daniel Geffken (CFO), and Rajesh Parekh (Director). Learn More on Eloxx Pharmaceuticals' active insiders.

Daniel E. Geffken Insider Trading History at Eloxx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2021Buy50,000$0.72$36,000.00View SEC Filing Icon  
See Full Table

Daniel E. Geffken Buying and Selling Activity at Eloxx Pharmaceuticals

This chart shows Daniel E Geffken's buying and selling at Eloxx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Eloxx Pharmaceuticals Company Overview

Eloxx Pharmaceuticals logo
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $0.00
Low: $0.00
High: $0.00

50 Day Range

MA: $0.38
Low: $0.00
High: $0.84

2 Week Range

Now: $0.00
Low: $0.00
High: $1.90

Volume

5,892 shs

Average Volume

12,256 shs

Market Capitalization

$628.00

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.63
True paradigm shift
From Porter & Company   |   Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.